Rapid Micro Biosystems Posts Record Revenue Growth on Key Biopharma Wins
Event summary
- Record Q4 2025 revenue of $11.3M, up 37% YoY, driven by biopharma system placements
- Full-year 2025 revenue hit $33.6M, 20% growth from 2024
- Amgen placed significant multi-system order in Q4 2025; Samsung Biologics followed in Q1 2026
- 2026 guidance projects $37M–$41M revenue with 30–38 system placements
- Non-GAAP gross margin expected to improve to ~20% in 2026
The big picture
Rapid Micro Biosystems' strong 2025 performance reflects growing biopharma demand for automated microbial quality control solutions. The company's ability to secure large orders from Amgen and Samsung Biologics underscores the strategic shift toward faster, more efficient manufacturing workflows in the biotech sector. However, maintaining margin expansion while scaling operations remains a key challenge.
What we're watching
- Customer Expansion
- Whether Amgen and Samsung Biologics' continued adoption will drive sustained demand for Growth Direct systems.
- Margin Improvement
- The pace at which Rapid Micro Biosystems can improve gross margins to ~20% amid rising operating expenses.
- Execution Risk
- How the company will manage cash flow and debt capacity under its $25M unused Trinity Capital facility.
Related topics